Invitation to Idorsia's webcast and conference call
An investor/analyst webcast and conference call will be held to discuss the
results of the Phase 3 PRECISION study of aprocitentan for patients with
resistant hypertension. These results are being presented as a late-breaking
science presentation during the American Heart Association (AHA) Scientific
Date: Tuesday , November 8 , 20 2 2
Time: 1 5 :00 CET / 1 4 :00 GMT / 0 8 :00 CST
The call will start with presentations by Martine Clozel, MD, Chief Scientific
Officer at Idorsia and Prof. Markus Schlaich, MD, FAHA, FESC, ISHF, The
University of Western Australia / Royal Perth Hospital and an investigator in
the PRECISION study followed by a Q&A session.
Dia l-in procedure :
1) Participants are required to register in advance of the conference (link
already open for registration) using the link provided below. Upon
registration, each participant will be provided with participant dial in
numbers, and a unique personal PIN.
2) In the 10 minutes prior to the call start time, participants will need to
use the conference access information provided in the e-mail received at the
point of registering. Participants may also use the Call Me feature instead of
dialing the nearest dial in number.
Online Registration : LINK
Webcast: Participants should go to the Idorsia website www.idorsia.com 10-15
minutes before the conference is due to start.
Replay: A replay of the investor webcast will be available through
www.idorsia.com approximately 60 minutes after the call has ended.
Andrew C. Weiss
Head of Investor Relations and Corporate Communications
Anhang Medienmitteilung PDF